Evidence map›Paper›PMID 33885911›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2021

Perillyl alcohol for pediatric TP53- and RAS-mutated SHH-medulloblastoma: an in vitro and in vivo translational pre-clinical study.

Marcela de Oliveira Silva, Graziella Ribeiro de Sousa, Sarah Capelupe Simões, Patrícia Nicolucci, Edwin Tamashiro, Fabiano Saggioro, Ricardo Santos de Oliveira, María Sol Brassesco

Abstract read
PubMed Publisher
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marcela de Oliveira SilvaRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
Graziella Ribeiro de SousaRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
Sarah Capelupe SimõesRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
Patrícia NicolucciPhysics Department from the Faculty of Philosophy, Sciences and Letters at Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil.
Edwin TamashiroRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
Fabiano SaggioroRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
Ricardo Santos de OliveiraRibeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
María Sol BrassescoLaboratory of Cell Biology and Oncogenetics, Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Av. Bandeirantes, 3900, Bairro Monte Alegre, Ribeirão Preto, São Paulo, CEP 14040-900, Brazil. solbrassesco@usp.br.ORCID 0000-0003-4447-784X
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInhalation of perillyl alcohol (POH) recently emerged as an investigational promising antiglioma strategy. However, little attention has been paid to its therapeutic potential for other brain tumors, especially in the pediatric setting.

methodsThe effects of POH were explored in medulloblastoma cell models belonging to the SHH variant with activation of RAS (ONS-76) or with TP53 mutations (DAOY and UW402), by means of proliferation and invasion assays. Interactions with methotrexate, thiotepa, or ionizing radiation were also assessed. Mice bearing subcutaneous tumors were treated with intraperitoneal injections. Alternatively, animals with intracranial tumors were exposed to intranasal POH alone or combined with radiation. Tumor growth was measured by bioluminescence. Analyses of cytotoxicity to the nasal cavity were also performed, and the presence of POH in the brain, lungs, and plasma was surveyed through chromatography/mass spectrometry.

resultsPOH decreased cell proliferation and colony formation, with conspicuous death, though the invasive capacity was only affected in the NRAS-mutated cell line. Median-drug effect analysis displayed synergistic combinations with methotrexate. Otherwise, POH showed to be a reasonable radiosensitizer. In vivo, intraperitoneal injection significantly decreased tumor volume. However, its inhalation did not affect orthotopic tumors, neither alone or followed by cranial irradiation. Nasal cavity epithelium showed unimportant alterations, though, no traces of POH or its metabolites were detected in tissue samples.

conclusionPOH presents robust in vitro antimedulloblastoma effects and sensitizes cell lines to other conventional therapeutics, reducing tumor volume when administered intraperitoneally. Nevertheless, further improvement of delivery devices and/or drug formulations are needed to better characterize its effectiveness through inhalation.

Indexed as

Antineoplastic AgentsCerebellar NeoplasmsMedulloblastomaAnimalsChildHedgehog ProteinsHumansMiceMonoterpenesras ProteinsTumor Suppressor Protein p53Antineoplastic AgentsHedgehog ProteinsMonoterpenesperillyl alcoholras ProteinsSHH protein, humanTP53 protein, humanTumor Suppressor Protein p53InhalationMedulloblastomaMethotrexatePerillyl alcoholPre-clinicalRadiotherapy

Identifiers

PMID33885911
OpenAlexW3153647742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.